Medtronic buys MacroPore product line for $21 million:
This article was originally published in Clinica
Executive Summary
Medtronic is to purchase San Diego, California-based MacroPore Biosurgery's Craniomaxillofacial/neurosurgical fixation product line for $21m in cash. Medtronic (Minneapolis, Minnesota) has been distributing the products for almost three years. The companies have also extended an existing co-development and supply agreement for spinal implants from 2005 to 2012. Neuer Markt-listed MacroPore will pay $4m to Medtronic for a waiver on the first rights to distribute MacroPore TS resorbable film product line in certain markets. MacroPore says the deals enable it to lower its operating costs, focus increasingly on biologics and invest in new market opportunities.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.